Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kaitlyn Andreano"'
Autor:
Rachid Safi, Suzanne E. Wardell, Kaitlyn Andreano, Steffi Oesterreich, Ching-Yi Chang, Donald P. McDonnell, Sunghee Park, Myles Brown, Sarah Sammons, Sandeep Artham, John D. Norris, Jennifer G. Baker, Rinath Jeselsohn
Publikováno v:
Molecular Cancer Therapeutics. 19:1395-1405
The estrogen receptor (ER/ESR1) is expressed in a majority of breast cancers and drugs that inhibit ER signaling are the cornerstone of breast cancer pharmacotherapy. Currently, aromatase inhibitors are the frontline endocrine interventions of choice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c70e648999333673bd4e6986eab1ff9
https://doi.org/10.1158/1535-7163.mct-19-1148
https://doi.org/10.1158/1535-7163.mct-19-1148
Autor:
Donald P. McDonnell, Fidel A. Valea, Matthew S. Jorgensen, Andrew Berchuck, Ching-Yi Chang, Julia A. Elvin, Meghan Steiner, Deborah A. Zajchowski, Brittany A. Davidson, Kaitlyn Andreano, Laura J. Havrilesky, Angeles Alvarez Secord, Stephanie Gaillard, Gerardo Colon-Otero
Publikováno v:
Gynecologic Oncology. 154:199-206
Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially arom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75f6b79f4a7871c70d480a80904d207
https://doi.org/10.1016/j.ygyno.2019.04.010
https://doi.org/10.1016/j.ygyno.2019.04.010
Autor:
Lauren M. Gutgesell, Kendall A. Heetderks, Jay C. Strum, Delita A. Thompson, John D. Norris, Rui Xiong, Debra A. Tonetti, Christina A. Chao, John E. Bisi, Suzanne E. Wardell, Kaitlyn Andreano, Jennifer G. Baker, Robert Baldi, Taylor K. Desautels, Jessica A. Sorrentino, Jiong Zhao, Gregory R. J. Thatcher, Yeeun Bae
Publikováno v:
Breast Cancer Research and Treatment
Purpose The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58127ad38a3705df557e41408d760f0d
https://pubmed.ncbi.nlm.nih.gov/32130619
https://pubmed.ncbi.nlm.nih.gov/32130619
Autor:
Suzanne E. Wardell, Kendall A. Heetderks, Taylor K. Desautels, Alexander P. Yllanes, Jeremy Blitzer, Kaitlyn Andreano, Donald P. McDonnell, Christina A. Chao, Yeeun Bae, John D. Norris
Publikováno v:
Translational cancer research
PurposeFulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4c1b27736eeaccb7c786b5e93b8e75f
https://pubmed.ncbi.nlm.nih.gov/32968620
https://pubmed.ncbi.nlm.nih.gov/32968620
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74551a82bcf08176c5aa6790b8b8dc66
https://doi.org/10.1096/fasebj.2019.33.1_supplement.815.4
https://doi.org/10.1096/fasebj.2019.33.1_supplement.815.4
Autor:
Stephanie Gaillard, Laurie M. Gay, Meghan Steiner, Kaitlyn Andreano, Brittany Anne Davidson, Laura Jean Havrilesky, Angeles Alvarez Secord, Fidel A. Valea, Gerardo Colon-Otero, Deborah A. Zajchowski, Ching-Yi Chang, Donald P. McDonnell, Andrew Berchuck, Julia Andrea Elvin
Publikováno v:
Journal of Clinical Oncology. 36:5590-5590
5590Background: Endocrine therapy is often considered to treat hormone-responsive gynecologic (gyn) malignancies. Mutations in ESR1 leading to constitutive transcriptional activity have been report...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::016f7094fc9710d9f1d9c0f0e91a7a24
https://doi.org/10.1200/jco.2018.36.15_suppl.5590
https://doi.org/10.1200/jco.2018.36.15_suppl.5590